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avathia,
zepril in pAbstract High-performance liquid chromatographic (HPLC) and UV spectrophotometric meth-
ods were developed and validated for the quantitative determination of amlodipine besylate
(AM) and benazepril hydrochloride (BZ). Different analytical performance parameters such as lin-
earity, precision, accuracy, speciﬁcity, limit of detection (LOD) and limit of quantiﬁcation (LOQ)
were determined according to International Conference on Harmonization ICH Q2B guidelines.
The RP-HPLC method was developed by the isocratic technique on a reversed-phase Shodex C-
18 5e column. The retention time for AM and BZ was 4.43 min and 5.70 min respectively. The
UV spectrophotometric determinations were performed at 237 nm and 366 nm for AM and at
237 nm for BZ. Correlation between absorbance of AM at 237 nm and 366 nm was established
and based on developed correlation equation estimation of BZ at 237 nm was carried out. The lin-
earity of the calibration curves for each analyte in the desired concentration range was good
(r2 > 0.999) by both the HPLC and UV methods. The method showed good reproducibility and
recovery with percent relative standard deviation less than 5%. Moreover, the accuracy and preci-
sion obtained with HPLC co-related well with the UV method which implied that UV spectroscopy
can be a cheap, reliable and less time consuming alternative for chromatographic analysis. The pro-
posed methods are highly sensitive, precise and accurate and hence successfully applied for deter-
mining the assay and in vitro dissolution of a marketed formulation.
ª 2013 King Saud University. Production and hosting by Elsevier B.V. All rights reserved.27439375, 27416409, mobile:
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A., Misra, M. Development and valida
ure and ﬁxed dose combination. Arabi1. Introduction
Amlodipine besylate (Fig. 1a), chemically 2-[(2-amino ethoxy)-
methyl]-4-(2-cholophenyl)-1,4-dihydro-6-methyl-3,5-pyridine
dicarboxylic acid 3-ethyl-5-methyl ester, benzosulfonate, is a
1,4-dihydropyridine calcium channel blocker which blocksier B.V. All rights reserved.
tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
an Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.043
Figure 1 Chemical structures of (a) amlodipine besylate (AM) and (b) benazepril hydrochloride (BZ).
2 A. Kavathia, M. Misrathe calcium entry by preventing the opening of voltage gated
L-type and T-type Ca-channels. It mainly affects heart and
smooth muscles inhibiting calcium entry caused by depolariza-
tion in these tissues (Joel and Alfred, 2001; Williams AD,
2002). Benazepril HCl (Fig. 1b), chemically (3S)-3-[(1S)-1-eth-
oxycarbonyl-3 phenylpropylamino]-2,3,4,5-tetrahydro-2-oxo-
1H-1-benzazepin-1-yl] acetic acid hydrochloride, is an antihy-
pertensive drug, which belongs to the group of angiotensin
convertase inhibitors. It acts on the renin–angiotensin–aldoste-
rone system by inhibition of the conversion of the inactive
angiotensin I to the highly potent vasoconstrictor angiotensin
II. It also reduces the degradation of bradykinin. It is applied
in pharmacotherapy as a ﬁrst choice drug for treatment of
arterial hypertension, ischemic heart disease, hypertrophy of
the left heart ventricle and post infarction heart dysfunction
(Healey et al., 2005; Joel and Alfred, 2001; Williams AD,
2002). Combination of both drugs into ﬁxed dose (FDCs)
has been an essential constituent in treatment of hypertension.
Literature survey reveals stability indicating UV spectro-
photometric (Gupta et al., 2010; Ramesh and Ramakrishna,
2011; Shama et al., 2009), RP-HPLC (C¸elebier M et al.,
2010; Chitlange et al., 2008; Kamble et al., 2010; Kasawar
and Farooqui, 2009; M Sarat and Rambabu, 2012; Shaalan
et al., 2013), HPLC in human serum (Bahrami and Mirzaeei,
2004), HPTLC (Chabukswar et al., 2010; Kamble et al.,
2010; Meyyanathan and Suresh, 2005) and LC–MS method
(Pilli et al.) for the estimation of AM alone and in combina-
tions. Several analytical methods have been reported for the
quantitative determination of BZ such as high performance li-
quid chromatography (HPLC) (Naidu et al., 2005), HPTLC-
densitometry (Meyyanathan and Suresh, 2005) and LC–MS
(Pilli et al., 2011). A major problem associated with simulta-
neous estimation of AM and BZ is that AM has kmax at
237 nm and it also shows absorbance at 366 nm and BZ has
kmax at 237 nm. As AM and BZ are having common kmax
(237 nm), direct estimation of BZ is not possible. So for the
estimation of AM and BZ simultaneously, a new analytical
method needs to be established. The spectrophotometric meth-
od based on simultaneous equation and the absorption ratio
method for simultaneous estimation of both drugs (Pawar
et al., 2011) is reported. Several RP-HPLC methods reported
for simultaneous estimation of AM and BZ involve estimation
of drug content at pH 3 which can reduce life span of column
(Kasawar and Farooqui, 2009; M Sarat and Rambabu, 2012;
Naidu et al., 2005). In the present work we have developed a
simple UV method for rapid simultaneous estimation of AM
and BZ using a correlation equation; obtained from absorbance
maxima of both AM and BZ. The values obtained from the
developed equation were also veriﬁed using HPLC. ThePlease cite this article in press as: Kavathia, A., Misra, M. Development and valida
estimation of amlodipine and benazepril in pure and ﬁxed dose combination. Arabiexisting HPLC method was further modiﬁed to reduce the
retention time. Both these methods are used to calculate drug
content in marketed formulation and in dissolution media.
2. Materials and methods
2.1. Reagent and chemicals
AM (Torrent Pharma Ltd.) and BZ (Astron Research Ltd.)
were received as gift sample. Marketed formulation
(AMACE-BP tablet, Madras Pharmaceuticals Ltd., India),
containing 5 mg of AM and 10 mg of BZ was procured from
local market. HPLC grade acetonitrile and puriﬁed grade
potassium di-hydrogen phosphate were purchased from
Fischer chemicals Ltd., India and Merck, India respectively.
All other reagents employed were of high purity analytical
grade. All weighing was done on a calibrated analytical bal-
ance. Calibrated glass wares were used throughout the work.
Double distilled water and Mili-Q water were used in the
UV method and RP-HPLC method respectively.
2.2. RP-HPLC method
2.2.1. Instrumentation
The HPLC method was performed on a system equipped with
a universal loop injector (Rheodyne 7725 i), Jasco UV-975
Intelligent UV/Vis detector and HPLC pump. The column
used was Shodex-RP C18 5e column (250 · 4.6 mm, 5 lm).
The mobile phase used was potassium dihydrogen phosphate
buffer: Acetonitrile (55:45 v/v) and the ﬁnal pH adjusted was
5.3 by using orthophosphoric acid. Injection volume was
50 lL. The ﬂow rate was set to 1 ml/min and detection of both
drugs was carried out at 237 nm by UV detector.
2.2.2. Chromatographic condition
The optimal composition of the mobile phase was determined
to be potassium dihydrogen phosphate buffer pH 5.3: Acetoni-
trile (55:45 v/v). The mobile phase was ﬁltered through nylon
0.22 lm membrane ﬁlter and was degassed before use
(30 min). Stock solution was prepared by dissolving AM and
BZ (10 mg each) that were weighed accurately and separately
transferred into 100 ml volumetric ﬂasks. Both drugs were dis-
solved in 25 ml of mobile phase to prepare standard stock solu-
tions. After the immediate dissolution, the volume was made
up to the mark with mobile phase. These standard stock solu-
tions were observed to contain 100 lg/ml of AM and BZ.
Appropriate volume from this solution was further diluted to
get appropriate concentration levels according to the require-tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
an Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.043
Development and validation of RP-HPLC and UV-spectrophotometric methods for rapid 3ment. From the above stock solutions, dilutions were made in
the concentration range of 1–6 lg/ml of both drugs. A volume
of 50 lL of each sample was injected into column.
2.2.3. Preparation of buffer
0.02 M potassium dihydrogen phosphate buffer of pH 5.3 was
used for method development. Buffer was prepared by dissolv-
ing 13.6 g of potassium dihydrogen phosphate by diluting with
Mili-Q water to 1000 ml. Then stock solution was further di-
luted to get 0.02 M Phosphate buffer. The pH was adjusted
by ortho-phosphoric acid using pH meter (Eutech Instru-
ments, Singapore). The prepared buffer was passed through
0.22 lm membrane ﬁlter (Milipore, USA) and the same was
used for mobile phase preparation.
2.2.4. Preparation of mobile phase
Mobile phase was prepared by mixing 0.02 M potassium di-
hydrogen phosphate buffer (pH 5.3) and acetonitrile (HPLC
grade) in 55:45 (v/v) proportions. Mixture was shaken vigor-
ously and sonicated for 30 min prior to use.
2.2.5. Preparation of stock solutions and test solutions (AM, BZ
and binary mixture)
Aqueous solution (100 lg/ml) of AM, BZ and its binary mix-
ture was prepared by adding accurately weighed 10 mg of AM
and BZ and binary mixture of both drugs in 50 ml of mobile
phase, then sonicated for 10 min and diluted up to 100 ml. Ser-
ies of test solutions were prepared in the concentration rangeTable 2 Summary of the HPLC method and UV method validatio
Parameters HPLC method
AM BZ
Working kmax 237 nm 237 nm
Beer’s law limit 1–6 lg/ml 1–6 lg/ml
Regression equation* y= 271730x+ 80905 y= 17543
Regression coeﬃcient (r2)
* 0.999 0.9991
SD of slope* 545 1614
SD of intercept* 1092 4383
Data point 6 6
Absorptivity* NA NA
Retention time (min)* 4.43 5.70
LOD* 0.074 0.053
LOQ* 0.223 0.161
* Average of six determination.
Table 1 UV method validation by using binary mixture of AM an
Concentration
(lg/ml)
Absorbance of
amlodipine at
366 nm (n= 6)
Absorbance of amlodipine at
237 nm based on equation
(y= 2.6751x  0.0024)
Absorb
binary
at 237
2 0.033 0.087 0.132
4 0.064 0.170 0.258
8 0.129 0.342 0.514
12 0.195 0.521 0.787
16 0.261 0.697 1.046
20 0.321 0.858 1.291
24 0.385 1.028 1.545
Please cite this article in press as: Kavathia, A., Misra, M. Development and valida
estimation of amlodipine and benazepril in pure and ﬁxed dose combination. Arabiof 1–6 lg/ml. by diluting appropriate volume of the stock solu-
tion (100 lg/ml) with mobile phase. The dilutions were ﬁrst
vortexed and then used for further analysis.
2.2.6. Preparation of calibration curve
The calibration curve was prepared by injecting concentration
of 1–6 lg/ml for AM, BZ and binary mixture solutions manu-
ally in triplicate to the HPLC system at detection wavelength
of 237.0 nm. Mean of n= 6 determinations was plotted as
the standard curve. The calibration curve was tested by vali-
dating it with inter-day and intra-day measurements. Linear-
ity, accuracy and precision were determined for both inter-
day and intra-day measurements.
2.3. UV spectrophotometric method
2.3.1. Instrumentation
The UV method was performed on SHIMADZU double beam
spectrophotometer (Model: UV-1800) with 2 nm spectral
bandwidth using 10 mm matched quartz cuvettes. Data acqui-
sition was done by using UV-probe software version 2.42. The
absorption spectra of reference and test solution were carried
out over the range of 200–400 nm.
2.3.2. Determination of wavelength of maximum absorbance
(kmax) of AM and BZ
Wavelength of maximum absorption was determined by scan-
ning 10 lg/ml solution of AM and BZ using UV–visible doublen.
UV-method
AM BZ
366 nm 237 nm
2–24 lg/ml 2–24 lg/ml
9x  6287.2 y= 0.0161x+ 0.0015 y= 0.0222x  0.001
0.999 0.999
0.0002 0.0001
0.0017 0.0011
7 7
0.017 0.0215
NA NA
0.291 0.070
0.883 0.212
d BZ.
ance of
mixture
nm (n= 6)
Absorbance of
benazepril in
binary mixture
Absorbance of
benazepril as per
calibration
curve (n= 6)
% RSD (Relative
standard
deviation)
0.044 0.045 1.220
0.087 0.086 0.550
0.171 0.174 1.019
0.266 0.264 0.396
0.348 0.354 0.782
0.433 0.446 1.481
0.516 0.529 1.216
tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
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4 A. Kavathia, M. Misrabeam spectrophotometer from 200 to 400 nm using 0.01 N
HCl as blank.
2.3.3. Preparation of stock solutions and test solutions (AM,
BZ and binary mixture)
Aqueous solutions (100 lg/ml) of AM, BZ and its binary
mixture were prepared by adding accurately weighed 10 mg
of AM and BZ and binary mixture of both drugs in 50 ml
of 0.01 N HCl, then sonicated for 10 min and diluted up to
100 ml. Series of test solutions were prepared in the concen-
tration range of 2–24 lg/ml by diluting appropriate volume
of the stock solution (10 lg/ml) with 0.01 N HCl. The dilu-
tions were ﬁrst vortexed and then used for further analysis.
2.3.4. Preparation of calibration curve
The calibration curve was prepared by scanning test samples
ranging from 2–24 lg/ml at 237 nm and 366 nm for AM and
at 237 nm for BZ. The calibration curve was tested by vali-
dating it with inter-day and intra-day measurements. Linear-
ity, intra-day and inter-day measurements, accuracy and
precision were determined for both. Mean of n= 6 determi-
nations was plotted as the standard curve.
2.3.5. Correlation equation method
Seven standard solutions of each drug having concentration
in the range of 2–24 lg/ml were prepared in 0.01 N HCl and
absorbance at 237 nm and 366 nm was measured. Mixed stan-
dards containing AM and BZ were also prepared (2–24 lg/
ml) and absorbance at 237 nm and 366 nm was measured.
Using these data a correlation was established between absor-
bance of AM at 237 nm and 366 nm. From the developed
correlation equation, absorbance of AM at 237 nm was gen-
erated with the help of absorbance at 366 nm. The method
validation was done on binary mixture of AM and BZ by
observing absorbance of AM at 366 nm and subtracting this
absorbance from total absorbance of binary mixture to obtain
absorbance of BZ, which was measured at 237 nm.
2.4. Method validation
2.4.1. Linearity
The methods were validated according to International Con-
ference on Harmonization Q2B guidelines (2005) for valida-
tion of analytical procedures in order to determine the
linearity, sensitivity, precision and accuracy for each analyte.
Calibration curves were generated with appropriate volumes
of working standard solutions for both UV and HPLC with
the range of 2–24 and 1–6 lg/ml respectively. The linearity
was evaluated by the least square regression method using
unweighted data.
2.4.2. Precision and accuracy
Both precision and accuracy were determined with standard
quality control samples (in addition to calibration standards)
prepared in triplicates at different concentration levels cover-
ing the entire linearity range. Precision is the degree of
repeatability of an analytical method under normal opera-
tional conditions. The precision of the assay was determined
by repeatability (intra-day) and intermediate precision (inter-
day) and reported as %R.S.D. for a statistically signiﬁcantPlease cite this article in press as: Kavathia, A., Misra, M. Development and validation of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
estimation of amlodipine and benazepril in pure and ﬁxed dose combination. Arabian Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.043
Development and validation of RP-HPLC and UV-spectrophotometric methods for rapid 5number of replicate measurements (Swartz and Krull, 1998).
The intermediate precision was studied by comparing the as-
says on 3 different days and the results documented as stan-
dard deviation and %R.S.D.
Accuracy is the percent of analyte recovered by assay from
a known added amount. For the measurement of accuracy
data from nine determinations over three concentration levels
covering the speciﬁed range were determined (Swartz and
Krull, 1998).
2.4.3. Speciﬁcity
The method speciﬁcity was assessed by comparing the chro-
matograms (HPLC) and scans (UV) obtained from the drug
and the most commonly used excipient mixture with those ob-
tained from blank (excipient solution in water without drug).
The excipients chosen are the ones used commonly in tablet
formulation, which included di-calcium phosphate (DCP), lac-
tose, starch, micro- crystalline cellulose (MCC), polyvinyl pyr-
rolidone (PVP), sodium starch glycolate (SSG) and magnesium
stearate. The drug to excipient ratio used was similar to that in
the commercial formulations.
2.4.4. LOD and LOQ
The limit of detection (LOD) is deﬁned as the lowest concen-
tration of an analyte that an analytical process can reliably dif-
ferentiate from background levels. The limit of quantiﬁcation
(LOQ) is deﬁned as the lowest concentration of the standard
curve that can be measured with acceptable accuracy, precision
and variability (ICH guideline Q2B, 2005). The LOD and
LOQ were calculated as
LOD ¼ 3:3r=S ð1Þ
LOQ ¼ 10r=S ð2Þ
Where r is the standard deviation of the lowest standard con-
centration and S is the slope of the standard curve.
2.5. Analysis of marketed tablet formulation (AMACE-BP)
Twenty tablets of marketed formulation (AMACE-BP) were
weighed and grounded to obtain ﬁne power. Accurately
weighed powder sample equivalent to 5 mg of AM andTable 4 Results of recovery study by HPLC and UV methods.
Method Drug Amt. present
(lg/ml)
Amt. added
(lg/ml)
Am
(lg/
HPLC
method
AM 2 1 2.9
2 2 3.9
2 3 4.9
BZ 2 1 2.9
2 2 3.9
2 3 4.9
UV
method
AM 10 8 17.9
10 12 21.9
10 16 25.9
BZ 10 8 17.9
10 12 21.9
10 16 25.9
* Average of six determinations.
Please cite this article in press as: Kavathia, A., Misra, M. Development and valida
estimation of amlodipine and benazepril in pure and ﬁxed dose combination. Arabi10 mg of BZ was dissolved in a 100 ml volumetric ﬂask con-
taining 0.01 N HCl. The solution was kept for sonication for
20 min, ﬁltered through Whatmann ﬁlter paper No. 41. Ali-
quot of this solution was diluted to produce the concentration
of 5 lg/ml for AM and 10 lg/ml for BZ (n= 6). The absor-
bance of sample solutions at 237 and 366 nm was measured
and the amount of drug present in the sample solution was cal-
culated in the same manner as that of pure mixed standard
solution. The results of analysis and statistical validation for
the marketed tablet formulation are reported in Table 3. The
results of recovery studies conducted by the addition of differ-
ent amounts of pure drugs at three different levels to a tablet
solution were found to be satisfactory and are given in Table 4.
2.6. In-vitro dissolution study
In-vitro dissolution study was performed on marketed formu-
lation AMACE-BP (6 tablets) by using USP type II apparatus.
Dissolution media used were 0.01 N HCl at 37 ± 2 C. Sam-
ples were taken at speciﬁc time intervals as per the FDA guide-
line and were analyzed by using the UV method and HPLC
method. Results were plotted as cumulative percentage release
(CPR) vs. time for both methods and were compared.
3. Result and discussion
3.1. RP-HPLC and UV-method validation
RP-HPLC and UV-Spectrophotometric methods were devel-
oped for AM and BZ which can be conveniently employed
for routine analysis in pharmaceutical dosage forms and will
eliminate unnecessary tedious sample preparations. The chro-
matographic conditions were optimized in order to provide a
good performance of the assay. The retention times (Rt) of
AM and BZ were 4.43 min and 5.70 min respectively. The
chromatograms have been shown in Fig. 2. A seven point cal-
ibration curve was constructed with working standards and
was found linear (r2P 0.999) for each of the analytes over
their calibration ranges. The slopes were calculated using the
plot of drug concentration versus area of the chromatogram.
The developed HPLC method was accurate, precise, reproduc-
ible and very sensitive.t. found*
ml)
Amt. recovered*
(lg/ml)
%
Recovery*
SD %
RSD
93 0.993 99.3 1.587 1.591
67 1.967 98.35 1.516 1.525
73 2.973 99.1 1.512 1.516
87 0.987 98.7 1.676 1.685
97 1.997 99.85 0.896 1.897
67 2.967 98.9 1.796 1.805
67 7.967 99.58 1.043 1.047
33 11.933 99.44 1.967 1.972
66 15.966 99.78 1.588 1.589
67 7.967 99.58 1.236 1.241
33 11.933 99.44 1.176 1.183
66 15.966 99.78 1.433 1.436
tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
an Journal of Chemistry (2013), http://dx.doi.org/10.1016/j.arabjc.2013.11.043
6 A. Kavathia, M. MisraFig. 3 shows overlay spectra of both drugs of the UV-Spec-
trophotometric method. The regression coefﬁcient of theFigure 2 Chromatogr
Figure 3 Overlay UV-sp
Figure 4 Correlation curve of absorbanc
Please cite this article in press as: Kavathia, A., Misra, M. Development and valida
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and the method was validated by using binary mixture of botham of AM and BZ.
ectra of AM and BZ.
e of AM between 237 nm and 366 nm.
tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
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Development and validation of RP-HPLC and UV-spectrophotometric methods for rapid 7drugs with less than 2% RSD (Table 1). All the method vali-
dation parameters are well within the limits as speciﬁed in
the ICH Q2B guidelines as shown in Table 2. The intra- and
inter-day precision (%R.S.D.) at different concentration levels
was found to be less than 2% (Table 3). Table 4 lists the per-
cent recovery (content uniformity) of both drugs in the com-
mercial formulations by HPLC and UV methods. Moreover
the %R.S.D. (less variation) shows good precision of both
developed methods. The calculated LOQ and LOD concentra-
tions conﬁrmed that the methods were sufﬁciently sensitive.
The methods were speciﬁc as none of the excipients interfered
with the analytes of interest (Table 5). Hence, the methods
were suitably employed for assaying both the drugs in com-
mercial marketed formulation (Table 6).Table 6 Assay of marketed formulation AMACE-BP by HPLC an
Assay Drug Label claimed (mg/tab) Amt. fo
HPLC method AM 5 4.90
BZ 10 9.90
UV method AM 5 4.97
BZ 10 9.91
* Standard deviation.
** Relative standard deviation.
*** Average of six determination.
Figure 5 In vitro dissolution study by
Table 5 Method speciﬁcity in the presence of excipients using
the HPLC method.
Excipient % AM * ± SD % RSD % BZ* ± SD % RSD
PVP 98.54 ± 0.72 0.73 98.48 ± 0.87 0.88
Mg stearate 99.49 ± 0.58 0.59 98.10 ± 0.93 0.94
SSG 98.43 ± 1.09 1.10 99.96 ± 1.03 1.03
Starch 97.92 ± 1.52 1.55 98.77 ± 1.18 1.19
MCC PH102 99.25 ± 1.57 1.58 99.49 ± 1.82 1.83
DCP 99.27 ± 1.76 1.77 95.70 ± 1.35 1.41
Lactose 97.16 ± 1.93 1.98 97.88 ± 1.56 1.59
* Average of six determinations.
Please cite this article in press as: Kavathia, A., Misra, M. Development and valida
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The average percentage drugs released within 75 min as de-
tected by the proposed UV method as well as the HPLC meth-
od after in vitro dissolution of tablets containing combination
drug product are depicted in Fig. 5. AM and BZ were com-
pletely released within 75 min of dissolution study and the
same could be measured using both the methods with almost
similar release pattern.
3.3. Statistical comparison of HPLC and UV methods
Statistical comparison was done on assay results obtained
from UV and HPLC methods for marketed formulation
(AMACE-BP) by using student’s t-test. Calculated values for
t-test were 1.47 and 2.01 for AM and BZ respectively which
is less than ttable value (2.306) indicating that there was no sig-
niﬁcant difference between the HPLC method and UV
method.
4. Conclusion
Simple, rapid, accurate and precise RP-HPLC as well as spec-
trophotometric methods have been developed and validated
for the routine analysis of AM and BZ in API and tablet
dosage forms. Both methods are suitable for the simultaneous
determination of AM and BZ in multi-component formula-d UV methods.
und (mg/tab)*** % Label claimed SD* % RSD**
98.00 1.89 1.93
99.04 1.62 1.64
99.40 1.83 1.84
99.10 2.54 2.55
the UV method and HPLC method.
tion of RP-HPLC and UV-spectrophotometric methods for rapid simultaneous
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8 A. Kavathia, M. Misrations without interference of each other. The developed meth-
ods are recommended for routine and quality control analysis
of the investigated drugs in two component pharmaceutical
preparations. The amount found from the proposed methods
was in good agreement with the label claim of the formulation.
Also the value of standard deviation and coefﬁcient of varia-
tion calculated were satisfactorily low, indicating the suitabil-
ity of the proposed methods for the routine estimation of
tablet dosage forms. The developed method can also be conve-
niently adopted for dissolution testing of AM and BZ in com-
mercial formulation.
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